Heidelberg Pharma announces financial figures and reports on successful business performance in 2023

First efficacy data from the clinical trial with HDP-101 in multiple myelomaExpansion of the ADC technology platform to include further payloadsNew Management Board teamSuccessful financing activities; sales revenue and other income above planConference call to be held on 25 March 2024 at 03:00 pm CET/ 10:00 am EDT&...

Related Keywords

Hangzhou ,Zhejiang ,China ,Huadong ,Guangdong ,Australia ,Germany ,Binghamton ,New York ,United States ,Delaware ,Indiana ,Cambridge ,Cambridgeshire ,United Kingdom ,Melbourne ,Victoria ,American ,Andreas Pahl ,Walter Miller ,Eli Lilly ,Heidelberg Pharma ,Jan Schmidt ,Drug Administration ,American Association For Cancer Research ,Heidelberg Pharma Research ,Binghamton University ,Huadong Medicine Co Ltd ,European Patent Office ,Good Laboratory Practice ,University Of New York ,Telix Pharmaceuticals ,Heidelberg Pharma Group ,Heidelberg Pharma Research Gmb ,Management Board ,Annual Report ,Chief Executive Officer ,Chief Financial Officer ,American Association ,Cancer Research ,Annual Meeting ,Heidelberg Pharma Research Gmbh ,New Management Board ,Chief Financial ,Managing Director ,Jan Schmidt Brand ,Supervisory Board ,Professor Andreas Pahl ,Emergence Therapeutics ,State University ,Magenta Therapeutics ,Partner Takeda Oncology ,Telix Pharmaceuticals Limited ,Biologics License Application ,Healthcare Royalty ,Executive Board ,